1 / 21

Hepatitis

Hepatitis. LINK. Viral Hepatitis is a group of disease that infect the liver. Three viruses - Hepatitis A, Hepatitis B and Hepatitis C are the most frequent viruses. Hepatitis A. Hepatitis A is a frequent virus of childhood and is not considered a deadly and serious infection.

yuma
Download Presentation

Hepatitis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatitis LINK Viral Hepatitis is a group of disease that infect the liver. Three viruses - Hepatitis A, Hepatitis B and Hepatitis C are the most frequent viruses.

  2. Hepatitis A • Hepatitis A is a frequent virus of childhood and is not considered a deadly and serious infection. • It is most commonly transmitted via the fecal-oral route through contaminated food or drinking water.

  3. Hepatitis A • Hepatitis A (HAV) has a single positive stranded (+) RNA in the genome. • No medications are prescribed for HAV, the body clears the infection on its own.

  4. Hepatitis B • Hepatitis B is an infectious viral disease transmitted by body fluids or needles (including unprotected sex) • Hepatitis B can cause severe acute infections and severe chronic infections.

  5. Hepatitis B • Health care workers are immunized against Hepatitis B • HBV has a double stranded DNA genome. • HBV infection can progress to cirrhosis (scarring of the liver) and hepatocellular cancer (HCC).

  6. Hepatocellular carcinoma = HCC The precise mechanism whereby hepatitis progresses to HCC is not known.

  7. Treatment of HBV

  8. Interferon alpha • Interferons are proteins produced by the immune system in response to viruses • Interferons serve to activate the immune system, specifically MHC 1 (major histocompatibility complex 1), thus giving a signal to T cells. • Link

  9. Pegylated Interferon alfa-2a • This protein derivative is formed by the addition of polyethylene glycol (structure above) to the interferon, leading to an enhanced lifetime of the interferon Link

  10. Nucleoside Analogs Approved for Treatment of HBV • These nucleoside analogs interfere with the action of the HBV reverse transcriptase (see link), becoming incorporated into the growing DNA strand and terminating reverse transcription. • Unfortunately, HBV can become resistant to these drugs. Adefovir dipivoxil Lamivudine Entecavir Telbivudine

  11. Hepatitis C (HCV) • Hepatitis C is transmitted through blood routes, needles, tattoos and sexual activity. • Hepatitis C is a quiet virus that may not be noticed • This virus may slowly eat away at your liver causing scarring and damage and finally almost total liver destruction. • Link

  12. Prevelance of HCV

  13. Hepatitis C (HCV) has a single positive stranded (+) RNA in the genome.

  14. Treatment of HCV • Current treatment is a combination off pegylated interferon alpha (Pegasys and PEG-Intron) combined with the antiviral drug ribavirin for a period of 24 to 48 weeks. • Link • Link • Link

  15. Ribavirin • Ribavirin resembles both adenosine and guanosine and may become incorporated into growing strands of RNA Ribavirin Adenosine Guanosine

  16. However the carboxamide group pairs equally well with both uracil or cytosine, thus leading to mutations in RNA-dependent RNA polymerases. • Ribavirin also acts as an inhibitor of inosine 5’-monophosphate dehydrogenase, a crucial enzyme in the biosynthesis of RNA. • Link

  17. Assigned Reading • Harris, J. Milton; Chess, Robert B. Effect of PEGylation on pharmaceuticals. Nature Reviews Drug Discovery (2003), 2(3), 214-221.

More Related